Befunolol HCl

• CAT Number: I023141
• CAS Number: 39543-79-8
• Molecular Formula: C16H22ClNO4
• Molecular Weight: 327.8
• Purity: 98%
• Synonyms: Befunolol HCl; Befunolol hydrochloride; Bentox; BFE 60; BFE-60; BFE60; Glauconex.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: Ethanone, 1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)-, hydrochloride
• InChI: InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
• InChIKey: TVVTWOGRPVJKDJ-UHFFFAOYSA-N
• SMILES: CC(C1=CC2=CC=CC(OCC(O)CNC(C)C)=C2O1)=O.[H]Cl

Befunolol HCl (Cat No.: I023141) is a non-selective beta-adrenergic receptor blocker with intrinsic sympathomimetic activity, primarily used in the treatment of glaucoma and ocular hypertension. It reduces intraocular pressure by decreasing aqueous humor production within the eye. Befunolol offers the advantage of effective pressure control with minimal systemic side effects. Its dual action as a beta-blocker and partial agonist makes it suitable for patients sensitive to other beta-blockers. It is also studied for its cardiovascular effects, particularly in managing mild hypertension and arrhythmias.

Reference

1: Nino M, Balato A, Ayala F, Balato N. Allergic contact dermatitis due to levobunolol with cross-sensitivity to befunolol. Contact Dermatitis. 2007 Jan;56(1):53-4. PubMed PMID: 17177718.
2: Shehata MA, El-Sayed GM, Abdel-Fattah LE. Utilization of 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) for kinetic spectrophotometric assay of befunolol hydrochloride in its pharmaceutical formulation. J AOAC Int. 2006 May-Jun;89(3):646-50. PubMed PMID: 16792064.
3: Reichl S, Müller-Goymann CC. The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. Int J Pharm. 2003 Jan 2;250(1):191-201. PubMed PMID: 12480285.
4: Nino M, Suppa F, Ayala F, Balato N. Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol. Contact Dermatitis. 2001 Jun;44(6):369. PubMed PMID: 11380552.
5: Zucchelli V, Silvani S, Vezzani C, Lorenzi S, Tosti A. Contact dermatitis from levobunolol and befunolol. Contact Dermatitis. 1995 Jul;33(1):66-7. PubMed PMID: 7493479.
6: Koike K, Horinouchi T, Takayanagi I. Comparison of interactions of R(+)- and S(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in the microsomal fractions from guinea-pig ciliary body, right atria and trachea. Gen Pharmacol. 1994 Nov;25(7):1477-81. PubMed PMID: 7896063.
7: Maruyama Y, Tanonaka K, Niwa T, Takeo S. Beneficial effects of befunolol on post-hypoxic recovery of cardiac contractility and myocardial metabolism. Arzneimittelforschung. 1992 Dec;42(12):1423-9. PubMed PMID: 1363193.
8: Fusco R, Greco GM, Del Prete A, Caccavale A, Nieto G, Sabbatino S, Santilli F. Long-term effects of befunolol on the corneal endothelium and the consensual ophthalmotonic reaction. Clin Ther. 1992 Nov-Dec;14(6):785-90. PubMed PMID: 1363082.
9: Mancuso G. Allergic contact dermatitis due to befunolol in eyedrops. Contact Dermatitis. 1992 Sep;27(3):198. PubMed PMID: 1360394.
10: Maruyama Y, Awaji T, Inoue M, Takeo S. Protective effects of befunolol on hypoxic respiration-induced alterations in myocardial energy metabolism of rats. Arzneimittelforschung. 1991 Oct;41(10):1022-6. PubMed PMID: 1799378.
11: Takayanagi I, Hagiwara H, Koike K, Hosokawa T, Kasuya Y. Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure. Can J Physiol Pharmacol. 1991 Aug;69(8):1243-5. PubMed PMID: 1685941.
12: Koike K, Hagiwara H, Takayanagi I. Comparison of interactions of R-(+)- and S-(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in isolated rabbit ciliary body and guinea-pig taenia caeci. Can J Physiol Pharmacol. 1991 Jul;69(7):951-7. PubMed PMID: 1683268.
13: Maruyama Y, Awaji T, Inoue M, Takeo S. Metabolic profile of beta-adrenoceptor-blocking action of befunolol. Arch Int Pharmacodyn Ther. 1991 May-Jun;311:73-88. PubMed PMID: 1686392.
14: Imamura Y, Nozaki Y, Higuchi T, Otagiri M. Reactivity for prostaglandins and inhibition by nonsteridal anti-inflammatory drugs of rabbit liver befunolol reductase. Res Commun Chem Pathol Pharmacol. 1991 Jan;71(1):49-57. PubMed PMID: 2024065.
15: Höh H. [The local anesthetic effect and subjective tolerance of 0.5% befunolol and 1% pindolol in healthy eyes]. Klin Monbl Augenheilkd. 1990 Apr;196(4):219-24. German. PubMed PMID: 1971855.
16: Nozaki Y, Imamura Y, Otagiri M. Kinetics of befunolol reductase from rabbit liver. Chem Pharm Bull (Tokyo). 1990 Jan;38(1):156-8. PubMed PMID: 2186874.
17: Yang L, Zheng JM. [Use of derivative UV spectroscopy to monitor the percutaneous absorption of befunolol-HCL]. Yao Xue Xue Bao. 1990;25(12):916-9. Chinese. PubMed PMID: 2104471.
18: Dorigo MT, Cerin O, Fracasso G, Altafini R. Cardiovascular effects of befunolol, betaxolol and timolol eye drops. Int J Clin Pharmacol Res. 1990;10(3):163-6. PubMed PMID: 1977708.
19: Takayanagi I, Ogishima M, Koike K. Thermodynamic analysis of beta-adrenergic partial agonists (befunolol and carteolol) interaction with low and high affinity binding sites of beta-adrenoceptors in guinea-pig taenia caecum. Gen Pharmacol. 1990;21(3):303-7. PubMed PMID: 1971246.
20: Imamura Y, Nozaki Y, Otagiri M. Purification and characterization of befunolol reductase from rabbit liver. Chem Pharm Bull (Tokyo). 1989 Dec;37(12):3338-42. PubMed PMID: 2698771.